PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
2.36%
Cash & equivalents growing 2.36% while TRVN's declined -30.51%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
2.36%
Below half of TRVN's -30.51%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.66%
Other current assets growth 50-75% of TRVN's -31.41%. Bruce Berkowitz notes fewer expansions. Possibly simpler working capital.
1.99%
Below half of TRVN's -30.59%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-7.06%
1.25-1.5x TRVN's -5.35%. Bruce Berkowitz notes a significant push to expand capacity faster than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both TRVN and the company show zero Long-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.24%
1.25-1.5x TRVN's -4.79%. Bruce Berkowitz checks if expansions surpass competitor's pace but remain justified.
No Data
No Data available this quarter, please select a different quarter.
1.71%
Below half of TRVN's -26.32%. Michael Burry sees a potential red flag for stagnation or capital shortage.
22.15%
Less than half of TRVN's -51.35%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Similar yoy growth to TRVN's -100.00%. Walter Schloss notes parallel approach to deferred revenue.
No Data
No Data available this quarter, please select a different quarter.
20.63%
Less than half of TRVN's -27.76%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Higher Deferred Tax Liabilities (Non-Current) Growth compared to TRVN's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-0.37%
Less than half of TRVN's -4.90%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
3.44%
Less than half of TRVN's -8.50%. David Dodd sees far fewer liability expansions relative to competitor.
6.90%
Less than half of TRVN's 16.67%. David Dodd sees fewer share issuances vs. competitor.
-3.28%
≥ 1.5x TRVN's -0.82%. David Dodd sees higher yoy retained profits than competitor.
100.00%
Higher AOCI Growth compared to TRVN's zero value, indicating worse performance.
-100.00%
Higher Other Stockholders' Equity Items Growth compared to TRVN's zero value, indicating worse performance.
-0.05%
Below half TRVN's -29.36%. Michael Burry sees potential underperformance in building shareholder capital.
1.71%
Below half TRVN's -26.32%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
0.63%
Higher Total Investments Growth compared to TRVN's zero value, indicating better performance.
-6.71%
Above 1.5x TRVN's -0.10%. Michael Burry sees a major jump. Investigate leverage rationale.
-2.57%
Less than half of TRVN's 55.16%. David Dodd sees better deleveraging or stronger cash buildup than competitor.